Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917945 | 1.00 | EGLN2 (0.52) | EGLN2EGLN1 | |
| SCHEMBL3924774 | 1.00 | EGLN2 (0.52) | EGLN2EGLN1 | |
| SCHEMBL6060923 | 0.89 | EGLN2 (0.47) | EGLN2EGLN1 | |
| SCHEMBL522777 | 0.85 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL964665 | 0.85 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL30402374 | 0.85 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL522778 | 0.85 | EGLN2 (0.68) | EGLN2EGLN1 | |
| SCHEMBL4111427 | 0.84 | EGLN1 (0.70) | EGLN2EGLN1 | |
| SCHEMBL522860 | 0.84 | EGLN2 (0.53) | EGLN2EGLN1 | |
| SCHEMBL522859 | 0.84 | EGLN2 (0.53) | EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | EGLN2 5/4885EGLN1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.